First Tracks Biotherapeutics

First Tracks Biotherapeutics https://validator.w3.org/feed/docs/rss2.html Privacy Policy Home Our Pipeline Terms of Use Rosnilimab Contact us Careers Eosinophilic Esophagitis Patients & Families ANB101 Our Science Celiac Disease First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases John Orwin Overview Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial John Schmid Dennis Fenton, Ph.D. About Us Daniel Faga Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis J. Anthony Ware, M.D. Magda Marquet, Ph.D. Rita Jain, M.D. ANB033